Wanbury

Why is Wanbury Ltd falling/rising?

As of 25-Jun, Wanbury Ltd's stock price is at 274.20, down 2.18% after two consecutive days of decline. Despite recent short-term underperformance, the stock has a year-to-date increase of 20.71%, indicating strong long-term performance.

As of 25-Jun, Wanbury Ltd's stock price is currently at 274.20, reflecting a decrease of 6.1 points or 2.18%. The stock has been underperforming, having fallen for the last two consecutive days, resulting in a total decline of 2.8% during this period. Additionally, the stock's performance today has underperformed the sector by 1.09%. <BR><BR>Despite these recent declines, it is noteworthy that Wanbury Ltd has shown strong performance over longer periods, with a year-to-date increase of 20.71%, significantly outperforming the Sensex, which has decreased by 9.53% in the same timeframe. However, in the last month, the stock has experienced a decline of 3.16%, while the Sensex has gained 0.80%. <BR><BR>Today's trading saw the stock reach an intraday low of Rs 271.45, which is a 3.16% drop. On a positive note, Wanbury is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally upward trend over a longer timeframe. Furthermore, there has been a rise in investor participation, with delivery volume increasing by 18.37% compared to the 5-day average, suggesting some level of interest despite the current price drop. <BR><BR>In summary, the recent decline in Wanbury Ltd's stock price can be attributed to short-term underperformance and consecutive losses, despite its strong long-term performance and rising investor participation.

Which are the latest news on Wanbury?

What does Wanbury do?

Wanbury Ltd is a pharmaceutical company involved in research and related activities, with a market cap of INR 914 Cr and reported net sales of 165 Cr and net profit of 22 Cr for March 2026. The company has a P/E ratio of 21.00 and a return on equity of 72.53%.

Overview:<BR>Wanbury Ltd is engaged in pharmaceutical and related activities, including research, and operates within the Micro Cap category in the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>Wanbury Ltd was incorporated in August 1988 and was formerly known as Pearl Organics Limited, adopting its current name in September 2004. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 165 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 22 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 914 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 21.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 2.77<BR>- Return on Equity: 72.53%<BR>- Price to Book: 15.67<BR><BR>Contact Details:<BR>Address: BSEL Tech Park B-Wing 10th Flr, Sector 30 A Opp Vashi Rly Stat Navi Mumbai Maharashtra : 400703<BR>Tel: 91-22-67942222<BR>Email: shares@wanbury.com<BR>Website: http://www.wanbury.com

How big is Wanbury?

As of 10th June, Wanbury Ltd has a market capitalization of 914.00 Cr, with recent net sales of 629.82 Cr and a net profit of 42.99 Cr. The company reported shareholder's funds of 59.27 Cr and total assets of 406.88 Cr for the period ending March 2025.

As of 10th June, Wanbury Ltd has a market capitalization of 914.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Wanbury reported Net Sales of 629.82 Cr and a Net Profit of 42.99 Cr.<BR><BR>For the reporting period of March 2025, the company had Shareholder's Funds amounting to 59.27 Cr and Total Assets of 406.88 Cr.

Who are in the management team of Wanbury?

The management team of Wanbury includes N K Puri (Independent Director), K Chandran (Vice Chairman & Whole Time Director), Jitendra J Gandhi (Company Secretary & Compliance Officer), and several other Independent Directors: Pallavi Shedge, Binod Chandra Maharana, Manisha Juvekar, Anupam Vaidya, and Pravin Dilip Pawar. This diverse team contributes to the company's governance and strategic direction.

The management team of Wanbury includes the following members:<BR><BR>1. **N K Puri** - Independent Director<BR>2. **K Chandran** - Vice Chairman & Whole Time Director<BR>3. **Jitendra J Gandhi** - Company Secretary & Compliance Officer<BR>4. **Pallavi Shedge** - Independent Director<BR>5. **Binod Chandra Maharana** - Independent Director<BR>6. **Manisha Juvekar** - Independent Director<BR>7. **Anupam Vaidya** - Independent Director<BR>8. **Pravin Dilip Pawar** - Independent Director<BR><BR>This team brings a diverse range of expertise to the company, contributing to its governance and strategic direction.

Who are the peers of the Wanbury?

Wanbury's peers include Fredun Pharma, Bajaj Healthcare, Fermenta Biotec, Themis Medicare, Bharat Parenter, Kopran, Sigachi Industries, Anlon Healthcare, and Remus Pharma. In terms of performance, Fredun Pharma leads with a 1-year return of 211.49%, while Wanbury's return is -13.83%.

Peers: The peers of Wanbury are Fredun Pharma, Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Bharat Parenter., Kopran, Sigachi Indust., Anlon Healthcare, Remus Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Anlon Healthcare, while Average management risk is found at Fredun Pharma, Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Bharat Parenter., Wanbury, Kopran, Sigachi Indust., and Remus Pharma. Growth is rated as Excellent for Anlon Healthcare and Fredun Pharma, Good for Wanbury and Remus Pharma, and Below Average for Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Bharat Parenter., Kopran, and Sigachi Indust. Capital Structure is Excellent for Sigachi Indust. and Remus Pharma, Good for Anlon Healthcare and Kopran, Average for Bharat Parenter., and Below Average for Wanbury, Fredun Pharma, Bajaj Healthcare, Fermenta Biotec., and Themis Medicare.<BR><BR>Return Snapshot: Fredun Pharma has the highest 1-year return at 211.49%, while Bajaj Healthcare has the lowest at -44.41%. Wanbury's 1-year return is -13.83%, which is significantly lower than Fredun Pharma's and higher than Bajaj Healthcare's. Additionally, peers such as Sigachi Indust. and Fermenta Biotec. have negative six-month returns.

Should I buy, sell or hold Wanbury Ltd?

When is the next results date for Wanbury Ltd?

The next results date for Wanbury Ltd is 14 May 2026.

The next results date for Wanbury Ltd is scheduled for 14 May 2026.

Is Wanbury technically bullish or bearish?

As of December 4, 2025, Wanbury's technical trend is mildly bearish, indicated by bearish momentum from the weekly MACD and KST, while daily moving averages and monthly indicators also reflect a cautious outlook.

As of 4 December 2025, the technical trend for Wanbury has changed from bearish to mildly bearish. The current technical stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish momentum, while the monthly MACD and Bollinger Bands suggest a mildly bearish outlook. The daily moving averages also reflect a mildly bearish sentiment. The lack of clear signals from the RSI and no trends in Dow Theory and OBV further support the neutral stance in the short term. Overall, the indicators suggest a cautious approach as the stock remains below its previous highs.

How has been the historical performance of Wanbury?

Wanbury's historical performance shows growth in net sales and operating income, increasing from 499.65 Cr in Mar'23 to 599.51 Cr in Mar'25. However, profitability declined, with profit before tax dropping to 29.55 Cr in Mar'25, and total liabilities rose to 406.88 Cr, indicating mixed financial health.

Answer:<BR>The historical performance of Wanbury shows a fluctuating trend in key financial metrics over the years, with notable changes in net sales, profits, and overall financial health.<BR><BR>Breakdown:<BR>Wanbury's net sales increased from 499.65 Cr in Mar'23 to 599.51 Cr in Mar'25, reflecting a positive growth trajectory. Total operating income followed a similar pattern, rising to 599.51 Cr in Mar'25 from 499.65 Cr in Mar'23. However, the company faced challenges with profitability, as operating profit (PBDIT) rose to 79.80 Cr in Mar'25 from 24.08 Cr in Mar'23, but profit before tax dropped to 29.55 Cr in Mar'25 from 56.34 Cr in Mar'24. Profit after tax also decreased to 30.53 Cr in Mar'25 from 55.96 Cr in Mar'24. The company's total liabilities increased to 406.88 Cr in Mar'25 from 337.62 Cr in Mar'24, while total assets also rose to 406.88 Cr in Mar'25 from 337.62 Cr in Mar'24, indicating a growing balance sheet. Cash flow from operating activities improved to 26.00 Cr in Mar'25 from 4.00 Cr in Mar'24, although cash flow from investing activities showed a significant outflow of -51.00 Cr in Mar'25. Overall, Wanbury's financial performance reflects a mix of growth in sales and operating income, alongside challenges in profitability and increasing liabilities.

Is Wanbury overvalued or undervalued?

As of November 6, 2025, Wanbury is considered undervalued with an attractive valuation grade, supported by a PE ratio of 20.53, strong growth potential indicated by a PEG ratio of 0.41, and impressive operational efficiency metrics like a 27.43% ROCE and 51.53% ROE, especially when compared to its more expensive peers like Sun Pharma and Divi's Laboratories.

As of 6 November 2025, the valuation grade for Wanbury has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued. Key ratios supporting this assessment include a PE ratio of 20.53, an EV to EBITDA of 11.90, and a PEG ratio of 0.41, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Wanbury's valuation stands out favorably against Sun Pharma Industries, which is considered expensive with a PE ratio of 35.02, and Divi's Laboratories, which is categorized as very expensive with a PE ratio of 79.09. Additionally, while Wanbury's ROCE is an impressive 27.43% and ROE is a remarkable 51.53%, these figures further highlight its operational efficiency and profitability relative to its peers. Despite recent underperformance against the Sensex in the year-to-date period, Wanbury's long-term returns over three and five years significantly outperform the index, reinforcing its attractive valuation.

Are Wanbury latest results good or bad?

Wanbury's latest results show strong annual growth, with a 118.3% increase in Profit Before Tax and a 23.90% rise in net sales. However, recent quarter-on-quarter declines in net sales and profit raise concerns, leading to a cautious outlook.

Wanbury's latest results present a mixed picture. On one hand, the company has shown significant growth in key financial metrics compared to previous quarters. For the quarter ending June 2025, Wanbury reported a Profit Before Tax (PBT) of Rs 13.26 crore, which is an impressive increase of 118.3% compared to the average PBT from the prior four quarters. Similarly, the Profit After Tax (PAT) rose by 76.7% to Rs 13.49 crore.<BR><BR>Additionally, Wanbury's net sales for the latest six months reached Rs 335.18 crore, reflecting a year-on-year growth of 23.90%. The cash and cash equivalents also improved, reaching Rs 12.83 crore, indicating better short-term liquidity.<BR><BR>However, there are concerns regarding the quarter-on-quarter performance. Wanbury experienced a decline in net sales by 5.13% and a significant drop in consolidated net profit by 33.42% compared to the previous quarter. These downward trends in key metrics suggest challenges in maintaining momentum.<BR><BR>Despite the overall positive annual growth, the recent quarter's performance and the 'Sell' call issued by MarketsMOJO indicate that there may be caution warranted regarding the stock. Therefore, while there are strong annual results, the recent quarterly performance raises some red flags.

Who are the top shareholders of the Wanbury?

The top shareholders of Wanbury include Expert Chemicals (India) Pvt Ltd with 30.53%, individual investors with 41.78%, and public shareholder Suresh Bhatia at 3.58%. Additionally, 7 Foreign Institutional Investors hold 1.55%, while pledged promoter holdings are at 76.74%.

The top shareholders of Wanbury include a mix of promoters and individual investors. The largest promoter is Expert Chemicals (India) Pvt Ltd, holding 30.53% of the shares. Additionally, individual investors collectively hold 41.78% of the company. The highest public shareholder is Suresh Bhatia, who owns 3.58%. There are also 7 Foreign Institutional Investors (FIIs) with a combined holding of 1.55%, while mutual funds currently do not hold any shares in the company. The pledged promoter holdings stand at 76.7355%.

Has Wanbury declared dividend?

Yes, Wanbury Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of July 29, 2010. However, the dividend yield is 0%, indicating that returns have primarily come from price appreciation rather than dividend income.

Wanbury Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: Jul-29-2010<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 5.38%, the dividend return was 0%, resulting in a total return of 5.38%.<BR><BR>In the 1-year period, the price return was 103.38%, the dividend return was 0%, resulting in a total return of 103.38%.<BR><BR>In the 2-year period, the price return was 420.47%, the dividend return was 0%, resulting in a total return of 420.47%.<BR><BR>In the 3-year period, the price return was 337.36%, the dividend return was 0%, resulting in a total return of 337.36%.<BR><BR>In the 4-year period, the price return was 179.36%, the dividend return was 0%, resulting in a total return of 179.36%.<BR><BR>In the 5-year period, the price return was 1328.57%, the dividend return was 0%, resulting in a total return of 1328.57%.<BR><BR>Overall, while Wanbury Ltd has declared a dividend, the dividend yield remains at 0%, indicating that the returns have primarily come from price appreciation rather than dividend income. The total returns over various periods show significant growth, particularly over the longer term.